Requip and Lymphoma - a phase IV clinical study of FDA data

Summary:

Lymphoma is reported as a side effect among people who take Requip (ropinirole hydrochloride), especially for people who are female, 60+ old, also take Protonix, and have Immunodeficiency common variable.

The phase IV clinical study analyzes which people have Lymphoma when taking Requip. It is created by eHealthMe based on reports of 21,866 people who have side effects when taking Requip from the FDA, and is updated regularly.

What is Requip?

Requip has active ingredients of ropinirole hydrochloride. It is often used in restless leg syndrome. eHealthMe is studying from 22,950 Requip users. Check the latest studies of Requip.

What is Lymphoma?

Lymphoma (cancer that begins in immune system cells) is found to be associated with 958 drugs and 1,013 conditions by eHealthMe. Check the latest studies of Lymphoma.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

21,866 people reported to have side effects when taking Requip.
Among them, 15 people (0.07%) have Lymphoma.

Among these 15 people:

What is the gender of people who have Lymphoma when taking Requip? *

female: 53.33 %
male: 46.67 %

What is the age of people who have Lymphoma when taking Requip? *

What are other drugs people take besides Requip? *

What are other side effects people have besides Lymphoma? *

Pneumonia: 8 people, 53.33%
Stress And Anxiety: 8 people, 53.33%
Weakness: 8 people, 53.33%
Fatigue (feeling of tiredness): 8 people, 53.33%
Anaemia (lack of blood): 7 people, 46.67%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 7 people, 46.67%
Malaise (a feeling of general discomfort or uneasiness): 7 people, 46.67%
Nausea (feeling of having an urge to vomit): 7 people, 46.67%
Nausea And Vomiting: 7 people, 46.67%
Swallowing Difficulty: 6 people, 40.00%

What are the existing conditions these people have? *

Primary Immunodeficiency Syndrome: 3 people, 20.00%
Immunodeficiency Common Variable: 3 people, 20.00%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 13.33%
Ventricular Fibrillation (abnormally irregular heart rhythm): 1 person, 6.67%
Sinus Disorder (disease of sinus): 1 person, 6.67%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 6.67%
Osteoporosis (bones weak and more likely to break): 1 person, 6.67%
Indigestion: 1 person, 6.67%
High Blood Cholesterol: 1 person, 6.67%
Heart Rate Irregular: 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Requip and have Lymphoma?

- Check whether Lymphoma is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Requip:

Requip (22,950 reports)

Lymphoma treatments and more:

Lymphoma (33,395 reports)

Browse all side effects of Requip:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Lymphoma:

Lymphoma (958 drugs)

Browse all the conditions that are associated with Lymphoma:

Lymphoma (1,013 conditions)

Related publications that referenced our studies

Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .

How the study uses the data?

The study uses data from the FDA. It is based on ropinirole hydrochloride (the active ingredients of Requip) and Requip (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.